Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1

Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1

According to clinical studies, statins improve the efficacy of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy for breast cancer; however, the underlying mechanisms are unclear. Herein, we showed that atorvastatin (ATO) decreased the content of PD-L1 in extracellular vesic...

Full description

Bibliographic Details
Main Authors: Eun-Ji Choe, Chan-Hyeong Lee, Ju-Hyun Bae, Ju-Mi Park, Seong-Sik Park, Moon-Chang Baek
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
statin
atorvastatin
extracellular vesicles
EV PD-L1
immunotherapy
Online Access:https://www.mdpi.com/1999-4923/14/8/1660

Internet

https://www.mdpi.com/1999-4923/14/8/1660

Similar Items